Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1–34

Mice heterozygous for targeted disruption of Pthrp exhibit, by 3 months of age, diminished bone volume and skeletal microarchitectural changes indicative of advanced osteoporosis. Impaired bone formation arising from decreased BM precursor cell recruitment and increased apoptotic death of osteoblast...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Miao, Dengshun, He, Bin, Jiang, Yebin, Kobayashi, Tatsuya, Sorocéanu, Maria A., Zhao, Jenny, Su, Hanyi, Tong, Xinkang, Amizuka, Norio, Gupta, Ajay, Genant, Harry K., Kronenberg, Henry M., Goltzman, David, Karaplis, Andrew C.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Clinical Investigation 2005
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC1193882/
https://ncbi.nlm.nih.gov/pubmed/16138191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI24918
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller